Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
biomatrix drug eluting stent
- Development stage
- Unknown
- Lead developer
- Biosensors International
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Implant, Percutaneous
01
Overview
The Biomatrix drug eluting stent is a family of coronary stents that utilize an abluminal biodegradable polymer coating to deliver Biolimus A9 (also known as BA9), a highly lipophilic sirolimus derivative. The mechanism of action involves local inhibition of the mammalian target of rapamycin (m-TOR) pathway in vascular smooth muscle cells, resulting in reduced neointimal hyperplasia and restenosis after percutaneous coronary intervention. The biodegradable poly-lactic acid (PLA) polymer matrix is absorbed within 6–9 months after implantation, leaving only the bare metal stent in place. This targeted delivery system minimizes systemic exposure and reduces long-term inflammatory response associated with permanent polymers. The Biomatrix platform includes several iterations such as Flex, NeoFlex, and Alpha models; all are designed for improved deliverability and vessel healing[1][4][5][6].
- Brand names
- BioMatrixBioMatrix FlexBioMatrix NeoFlexBioMatrix Alpha
- Other names
- biolimus-eluting stentBES
02
Targets
Mechanistic target of rapamycin complex 1FKBP1A
Beyond the preview
Go deeper on biomatrix drug eluting stent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on biomatrix drug eluting stent.